Adaptive immunotherapy of the advanced prostate cancer - Cancer Testis Antigen (CTA) as possible target antigens;Adaptive immuntherapie des fortgeschrittenen prostatakarzinoms - Cancer Testis Antigene (CTA) als mögliche zielantigene

Aktuelle Urologie

Volumn 35, Issue 4, 2004, Pages 326-330

  Prikler, L ^a,e   Scandella, E ^b   Men, Y ^b   Engeler, D S ^a   Diener, P A ^d   Gillessen, S ^c   Ludewig, B ^b   Schmid, H P ^a  

^a Klinik für Urologie Universitätsspitals Basel Kantonsspitals Baseband   (Switzerland)

^b Laborforschungsabteilung ^*  (Switzerland)

^c Klinik für Onkologie   (Switzerland)

^d Kantonsspital St Gallen   (Switzerland)

^e Kantonsspital St Gallen Klinik fur Urologie   (Switzerland)

Author keywords

Cancer testis antigens; Dendritic cells; Immunotherapy; Prostatic cancer

Indexed keywords

CANCER TESTIS ANTIGEN; IMMUNOMODULATING AGENT; LAGE 1 ANTIGEN; MAGE C2 ANTIGEN; NY EO 1 ANTIGEN; PAGE4 ANTIGEN; PRAME ANTIGEN; SSX 2 ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; PROSTATE CANCER;

ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CANCER VACCINES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MALE; MEMBRANE PROTEINS; MICE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TESTIS; TUMOR CELLS, CULTURED;

EID: 4644296375     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-818510     Document Type: Article

References (51)

1. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186 (7): 1177-1182
2. Austyn JM, Hankins DF, Larsen CP, Morris PJ, Rao AS, Roake JA. Isolation and characterization of dendritic cells from mouse heart and kidney. J Immunol 1994; 152 (5): 2401-2410
3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392 (6673): 245-252
4. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106 (3): 271-274
5. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184 (2): 465-472
6. Brinkmann U, Vasmatzis G, Lee B, Yerushalmi N, Essand M, Pastan I. PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus. Proc Natl Acad Sci U S A 1998; 95(18): 10757-10762
7. Brossart P, Zobywalski A, Grunebach F, Behnke L, Stuhler G, Reichardt VL, Kanz L, Brugger W. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res 2000; 60 (16): 4485-4492
8. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997; 388 (6644): 782-787
9. Dannull J, Diener PA, Prikler L, Furstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000; 60 (19): 5522-5528
10. Dutoit V, Taub RN, Papadopoulos KP, Talbot S, Keohan ML, Brehm M, Gnjatic S, Harris PE, Bisikirska B, Guillaume P et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 2002; 110(12): 1813-1822
11. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6 (5): 1632-1638
12. Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994; 24 (3): 605-610
13. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18: 245-273
14. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2 (1): 52-58
15. Iavarone C, Wolfgang C, Kumar V, Duray P, Willingham M, Pastan I, Bera TK. PAGE4 is a cytoplasmic protein that is expressed in normal prostate and in prostate cancers. Mol Cancer Ther 2002; 1 (5): 329-335
16. La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism. J Immunol 1999; 162 (8): 4817-4823
17. Ludewig B, McCoy K, Pericin M, Ochsenbein AF, Dumrese T, Odermatt B, Toes RE, Melief CJ, Hengartner H, Zinkernagel RM. Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol 2001; 166 (6): 3678-3687
18. Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 2000; 12 (5): 571-575
19. Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 2000; 38 (2): 208-217
20. Morant R, Hsu Schmitz SF, Bernhard J, Thurlimann B, Borner M, Wernli M, Egli F, Forrer P, Streit A, Jacky E et al. Vinorelbine in androgen-independent metastatic prostatic carcinoma - a phase II study. Eur J Cancer 2002; 38 (12): 1626-1632
21. Muller S, Hanisch FG. Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation. J Biol Chem 2002; 277 (29): 26103-26112
22. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998; 16 (4): 364-369
23. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4 (3): 328-332
24. Nestle FO. Dendritic cell vaccination for cancer therapy. Oncogene 2000; 19(56): 6673-6679
25. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999; 96 (5): 2233-2238
26. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, Hemnni S, Hengartner H, Zinkernagel RM. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001; 411 (6841): 1058-1064
27. Ossevoort MA, Feltkamp MC, Veen KJ van, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995; 18 (2): 86-94
28. Pantuck AJ vOA, Gitlitz BJ et al. MUC-1-IL-2 gene therapy for advanced prostate cancer: phase I trial and clinical response associated systemic immune activation (abstract). J Urol 2000; 163(suppl): 158
29. Pardoll DM. Cancer vaccines. Nat Med 1998; 4 (5 Suppl): 525-531
30. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2 (4): 227-238
31. Pierre P, Turley SJ, Gatti E, Hull M, Meltzer J, Mirza A, Inaba K, Steinman RM, Mellman I. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 1997; 388 (6644): 787-792
32. Rea D, Havenga MJ, Assem M van Den, Sutmuller RP, Lemckert A, Hoeben RC, Bout A, Melief CJ, Offringa R. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 2001; 166 (8): 5236-5244
33. Reis e Sousa C, Stahl PD, Austyn JM. Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med 1993; 178(2): 509-519
34. Romani N, Koide S, Crowley M, Witmer-Pack M, Livingstone AM, Pathman CG, Inaba K, Steinman RM. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 1989; 169 (3): 1169-1178
35. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180 (1): 83-93
36. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233(4770): 1318-1321
37. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001; 7 (8): 2277-2284
38. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179(4): 1109-1118
39. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995; 182 (2): 389-400
40. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994; 151 (3): 622-628
41. Scanlan MJ, Cure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188: 22-32
42. Scholfield DP, Simms MS, Bishop MC. MUC1 mucin in urological malignancy. BJU Int 2003; 91 (6): 560-566
43. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59 (20): 5160-5168
44. Slingluff CL. Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms. Cancer Immunol Immunother 1999; 48 (7): 371-373
45. Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA, Crystal RG. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186 (8): 1247-1256
46. Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997; 186 (8): 1213-1221
47. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002; 109(12): 1519-1526
48. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev 1999; 170: 85-100
49. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 1997; 186 (2): 229-238
50. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997; 156: 199-209
51. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183 (1): 87-97